Literature DB >> 20636237

Effect of recombinant human keratinocyte growth factor (Δ23rHuKGF, Palifermin) on inflammatory and immune changes in mouse tongue during fractionated irradiation.

Jana Jaal1, Caroline Richter, Wolfgang Dörr.   

Abstract

PURPOSE: A significant reduction in the incidence of radiation-induced oral mucositis by Palifermin has been demonstrated. The underlying mechanisms, however, remain unclear. The aim of the present study was to assess the effect of Palifermin on inflammatory and immune processes during fractionated irradiation in mouse tongue.
MATERIALS AND METHODS: Fractionated irradiation, 10 x 3 Gy in two weeks, was given to the snout of the animals. In one group, a single injection of Palifermin (15 mg/kg, s.c.) was given one day before the onset of radiotherapy. Groups of mice (n = 3) were sacrificed from day 1-16 after the start of irradiation. Vasodilatation, endothelial expression of intercellular adhesion molecule 1 (ICAM-1) and the number of CD105-positive (CD105(+)) macrophages were assessed.
RESULTS: Compared to untreated control tissue, irradiation resulted in a significant vasodilatation and an increase in endothelial ICAM-1 staining intensity during the entire study period. Additionally, a significant increase in the number of CD105(+) macrophages was detected. In contrast, with Palifermin treatment before irradiation, none of these changes were found within the first 10 days.
CONCLUSION: Palifermin pre-treatment resulted in a long-lasting inhibition of radiation-induced inflammatory and immune changes in mouse tongue. This may contribute to the protective effect of this growth factor.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20636237     DOI: 10.3109/09553002.2010.487025

Source DB:  PubMed          Journal:  Int J Radiat Biol        ISSN: 0955-3002            Impact factor:   2.694


  6 in total

Review 1.  [Radiation biology of normal tissues. Scientific progress and perspectives].

Authors:  W Dörr; C Herskind
Journal:  Strahlenther Onkol       Date:  2012-11       Impact factor: 3.621

2.  Modulation of radiation-induced oral mucositis by thalidomide : Preclinical studies.

Authors:  Katharina Frings; Sylvia Gruber; Peter Kuess; Miriam Kleiter; Wolfgang Dörr
Journal:  Strahlenther Onkol       Date:  2016-06-09       Impact factor: 3.621

Review 3.  Oral Mucositis: An Update on Innate Immunity and New Interventional Targets.

Authors:  C Chen; Q Zhang; W Yu; B Chang; A D Le
Journal:  J Dent Res       Date:  2020-06-01       Impact factor: 8.924

Review 4.  Mechanisms of radiation-induced normal tissue toxicity and implications for future clinical trials.

Authors:  Jae Ho Kim; Kenneth A Jenrow; Stephen L Brown
Journal:  Radiat Oncol J       Date:  2014-09-30

5.  Systemic administration of heparin ameliorates radiation-induced oral mucositis-preclinical studies in mice.

Authors:  Maria Kowaliuk; Eva Bozsaky; Sylvia Gruber; Peter Kuess; Wolfgang Dörr
Journal:  Strahlenther Onkol       Date:  2018-04-16       Impact factor: 3.621

6.  Protective effects of systemic dermatan sulfate treatment in a preclinical model of radiation-induced oral mucositis.

Authors:  Sylvia Gruber; Katharina Frings; Peter Kuess; Wolfgang Dörr
Journal:  Strahlenther Onkol       Date:  2018-03-01       Impact factor: 3.621

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.